JPH069363A - Medicinal cosmetic - Google Patents

Medicinal cosmetic

Info

Publication number
JPH069363A
JPH069363A JP4169807A JP16980792A JPH069363A JP H069363 A JPH069363 A JP H069363A JP 4169807 A JP4169807 A JP 4169807A JP 16980792 A JP16980792 A JP 16980792A JP H069363 A JPH069363 A JP H069363A
Authority
JP
Japan
Prior art keywords
cosmetic
eczema
dermatitis
acne
zinc oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP4169807A
Other languages
Japanese (ja)
Other versions
JP2697999B2 (en
Inventor
Setsuko Tsuda
攝子 津田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FUIRU INTERNATL KK
Original Assignee
FUIRU INTERNATL KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FUIRU INTERNATL KK filed Critical FUIRU INTERNATL KK
Priority to JP4169807A priority Critical patent/JP2697999B2/en
Publication of JPH069363A publication Critical patent/JPH069363A/en
Application granted granted Critical
Publication of JP2697999B2 publication Critical patent/JP2697999B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To provide the medicinal cosmetic useful for preventing the exacerbation of chronic acne, eczema or dermatitis by adding zinc oxide to cosmetic materials. CONSTITUTION:30-60wt.% of zinc oxide as an active ingredient is added to the materials of a cosmetic such as a cream, pack, emulsion or foundation to provide the medicinal cosmetic. The medicinal cosmetic is used for men having skin natures susceptible to acne, eczema, dermatitis, etc., or for the serious patients of the eczema or dermatitis requiring special treatments as a daily cosmetic without being used as an external medicine, thereby permitting to protect the skins, improve the syndromes and prevent the exacerbation of the syndromes. The medicinal cosmetic can prevent the skins from external factors, e.g. allergic factors such as pollen, mites, sweats, or UV rays which cause subcorneal disorders.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は薬用化粧品に関し、殊
に、ざそう(ニキビ)、湿疹、皮膚炎等の患者に対して
用いられる薬用化粧品に関する。
FIELD OF THE INVENTION The present invention relates to a cosmeceutical product, and more particularly to a cosmeceutical product used for patients with acne, eczema, dermatitis and the like.

【0002】[0002]

【従来の技術】酸化亜鉛は亜鉛華とも称し、皮膚に対し
て局所収斂作用、消炎作用、保護作用及び軽度の防腐作
用があり、古くから皮膚の湿疹、創面、皮膚炎などの外
用治療薬として使用され、長期間使用しても副作用のな
いことが知られている。一般的な外用薬としては散剤、
軟膏、液剤(懸濁剤、ローション、リニメント剤)等と
して使用される。
BACKGROUND OF THE INVENTION Zinc oxide, also called zinc white, has local astringent, anti-inflammatory, protective and mild antiseptic effects on the skin, and has long been used as an external therapeutic agent for skin eczema, wounds, dermatitis, etc. It is used and is known to have no side effects even after long-term use. As a general topical drug, powder
Used as an ointment, liquid (suspension, lotion, liniment) and the like.

【0003】皮膚疾患、特にニキビ、湿疹、皮膚炎の慢
性的重症の例においては、抗生物質やホルモン剤等を用
いる皮膚科専門治療を長期間施した場合には、さまざま
な副作用を発生する虞があるので、ある程度症状が落ち
ついた段階で治療を中止せざるを得ないことが多い上、
患者自身も長期治療をしたがらないなどの理由から、こ
れらは慢性疾患となり、なかなか完治せず、すぐに再燃
してくるケースが多く見られる。特に女性患者では、顔
面にこれらの病変があればある程度、化粧を厚塗りして
目立たないように隠そうとする傾向が強く、それによる
ニキビの悪化や、化粧かぶれを起こしやすい。これによ
ってさらに病変は慢性的に悪化をもたらすということに
なる。従って、長期間(3カ月以上10年間)に亘り治
療しても、再燃と寛解を繰り返して治療に一層長期化す
ることが避けられない。
In the case of chronic severe cases of skin diseases, especially acne, eczema, and dermatitis, various side effects may occur when a dermatological specialty treatment using antibiotics, hormones and the like is applied for a long period of time. Therefore, treatment is often forced to stop when the symptoms have subsided, and
Because patients themselves do not want to be treated for a long period of time, these often become chronic diseases, they do not completely cure, and they often relapse soon. Particularly in female patients, if these lesions are present on the face, they tend to thickly apply makeup to some extent to hide them inconspicuously, resulting in worsening of acne and cosmetic rashes. This also means that the lesions will be exacerbated chronically. Therefore, even if the treatment is performed for a long period (3 months or more and 10 years), it is inevitable that relapse and remission are repeated and the treatment is further prolonged.

【0004】[0004]

【発明が解決しようとする課題】本発明は、ざそう、湿
疹、皮膚炎などのでき易い肌質を有する人、もしくはざ
そう、湿疹、皮膚炎の重症例患者であって専門的治療に
より症例が軽快した人、に対して外用薬でなく、化粧品
として使用して、皮膚を防御・保護し、これらの症状を
改善・再燃を抑止して、予防することを目的とする。
DISCLOSURE OF THE INVENTION The present invention provides a person who has a skin quality such as acne, eczema, dermatitis or the like, or a severe case patient with acne, eczema, dermatitis, which is treated by professional treatment. The purpose of the present invention is to prevent and protect skin by using it as a cosmetic rather than an external medicine for those who have relieved, to improve and prevent these symptoms and to prevent relapse.

【0005】[0005]

【課題を解決するための手段】上記目的を達成するた
め、本発明の特徴構成は、クリーム、パック、乳液、フ
ァンデーションなどの化粧品材料に酸化亜鉛が30〜6
0%(重量)配合されたことにある。本発明は、ざそ
う、湿疹、皮膚炎の再燃予防用として用いられることが
好ましい。殊に、ざそう、湿疹、皮膚炎のでき易い肌質
を有する人、もしくはざそう、湿疹、皮膚炎の重症例患
者であって専門的治療により症例が軽快した人、に対す
る再燃予防用に基礎化粧品材料として用いられることが
適している。
To achieve the above object, the present invention is characterized in that cosmetic materials such as creams, packs, emulsions and foundations contain 30 to 6 zinc oxide.
0% (weight) is included. The present invention is preferably used for preventing relapse of acne, eczema and dermatitis. Basically, for preventing flare-up, especially for people who have a skin quality that is prone to acne, eczema, and dermatitis, or for patients with severe cases of acne, eczema, and dermatitis who have had their cases relieved by specialized treatment. It is suitable to be used as a cosmetic material.

【0006】[0006]

【作用】本発明によれば、日常的な使用する化粧品とし
て、殊に基礎化粧品として、ざそう、湿疹、皮膚炎ので
き易い人と、それらの重症例でも、専門的治療により軽
快した人に用いることにより、皮診の再燃を予防する作
用をもたらす。現在問題となっているアレルギー因子な
ど、角層障害を起こし得る外的因子(花粉、ダニ、汗、
紫外線など)から肌を守る優れた防御的作用により、障
害に悩む皮膚を健康な皮膚へと導くことを可能ならしめ
る。
EFFECTS OF THE INVENTION According to the present invention, as a cosmetic for daily use, especially as a basic cosmetic, it is suitable for people who are prone to acne, eczema, and dermatitis, and for those who have severe cases, who are relieved by specialized treatment. By using it, it brings about the effect of preventing the flare-up of skin examination. External factors (pollen, mites, sweat, sweat,
It has an excellent protective effect that protects the skin from (UV rays, etc.), which makes it possible to lead damaged skin to healthy skin.

【0007】化粧品材料、特に基礎化粧品材料として
は、一般に使用されている女性または男性用の、例えば
クリーム、パック、乳液、ローション、ファンデーショ
ン等の固形、ペースト、液状のものが適宜選択使用され
る。酸化亜鉛は結晶性粉末で、水、酢酸、メタノール、
エタノール、エーテルには殆ど不溶であるから、液剤の
場合には微粉末を適宜の分散剤、懸濁剤を加えた懸濁液
として使用することが望ましい。これらの化粧品材料に
酸化亜鉛を30〜60%、好ましくは35〜40%(重
量)を公知の適当な手段により均一に配合して化粧品を
製造する。
As a cosmetic material, particularly a basic cosmetic material, a solid, paste, or liquid material such as cream, pack, emulsion, lotion, foundation, etc., which is generally used for women or men, is appropriately selected and used. Zinc oxide is a crystalline powder, water, acetic acid, methanol,
Since it is almost insoluble in ethanol and ether, it is desirable to use a fine powder in the case of a liquid agent as a suspension containing an appropriate dispersant and suspending agent. Zinc oxide is uniformly mixed with these cosmetic materials in an amount of 30 to 60%, preferably 35 to 40% (by weight) by a known appropriate means to produce a cosmetic product.

【0008】酸化亜鉛の配合量が30%以下では治療効
果が充分ではなく、また60%以上になると塗布時の伸
びが悪くなり、ザラザラした感じとなり化粧品としては
好ましくない。液剤では多量の酸化亜鉛の懸濁が困難
で、最も好ましいのは酸化亜鉛を40%前後配合したク
リームまたはパックである。
When the content of zinc oxide is 30% or less, the therapeutic effect is not sufficient, and when it is 60% or more, the elongation at the time of application becomes poor and the material feels gritty, which is not preferable for cosmetics. Suspension of a large amount of zinc oxide is difficult with a liquid formulation, and the most preferred is a cream or pack containing about 40% zinc oxide.

【0009】酸化亜鉛は、従来から薬用外用薬としての
みならず、粉末顔料として一部化粧品には、タルク、カ
オリン、酸化チタン、酸化鉄、一般有機顔料などと共に
使用されるが、クリーム、パック、乳液、ファンデーシ
ョン等の化粧品として一般には数%配合されているにす
ぎない。
Zinc oxide has hitherto been used not only as a topical drug for external use but also as a powder pigment in some cosmetics together with talc, kaolin, titanium oxide, iron oxide, general organic pigments, creams, packs, In general, cosmetics such as milky lotion and foundation are generally mixed in only a few percent.

【0010】本発明では、これらの化粧品に対して通常
使用量を越えた少なくとも30%を越え、好ましくは3
5%以上の多量を配合して、ざそう、湿疹、皮膚炎の再
燃抑制用化粧品としたことに特徴がある。化粧品として
は女性用化粧品が特に望ましく、女性の場合には特徴的
にざそう例症では女性ホルモンのバランスが乱れて月経
前に皮膚病変の増悪が現れやすく、また胃腸障害を起こ
す例も多く抗生物質投与後ではこれらの症状が顕著に出
現する。更に、慢性の湿疹、皮膚炎ではホルモン剤投与
によって完治し難く長期化し、化粧かぶれをおこす場合
が多い。
According to the invention, these cosmetics are used in an amount of at least 30%, which is more than the usual amount, preferably 3%.
It is characterized by being blended in a large amount of 5% or more to make a cosmetic for suppressing flare-up of acne, eczema and dermatitis. Women's cosmetics are especially desirable as cosmetics, and in the case of females, peculiar cases of pimples are likely to cause an exacerbation of skin lesions before menstruation due to imbalance of female hormones, and there are many cases of gastrointestinal disorders. These symptoms are prominent after administration of the substance. Further, in chronic eczema and dermatitis, administration of hormones makes it difficult to completely cure and prolongs the period, often causing a cosmetic rash.

【0011】本発明は薬用化粧品であるため、日常的な
化粧を行うことによってこれらの慢性疾患に対して有効
であり、適用後1カ月以内でも各種の症状改善が認めら
れた。同時に、化粧品によるいわゆる化粧かぶれを防止
する効果がある。しかも、湿疹、皮膚炎および化粧かぶ
れを起こし易い肌質の人も、長期間安全に使用すること
ができる。
Since the present invention is a cosmeceutical product, it is effective against these chronic diseases by applying daily makeup, and various symptom improvement was observed even within 1 month after application. At the same time, it has an effect of preventing so-called makeup rash caused by cosmetics. In addition, people with skin qualities that are prone to eczema, dermatitis, and rashes of makeup can be safely used for a long period of time.

【0012】化粧品材料としては、クリーム、パスタ、
パック、乳液、ファンデーション等適宜のものがあげら
れるが、酸化亜鉛の配合量が多い関係からクリーム、パ
ック等の固形、ペースト状のものがより適当である。こ
れらは一般に使用される成分、例えば油剤として流動パ
ラフィン、セレシン、じろう、ラノリン、ワセリン、セ
タノール、スクワレン、ホホバ油、ステアリン酸、パル
ミチン酸、ラウリルアルコール、ステアリルアルコー
ル、セチルアルコール、ミツロウ、メチルポリシロキサ
ン、ジメチルシクロポリシロキサン等が用いられ、保湿
作用のプロパノール、グリコール、プロピレングリコー
ル、ヒアルロン酸、コラーゲン、ポリエチレングリコー
ル、ヒドロキシステアリン酸コレステリル、グリセリ
ン、ソルビトールの他各種の界面活性剤、乳化剤、増粉
剤、PH調整剤、酸化防止剤、色素、香料、紫外線吸収
剤などを適宜配合してもよい。
Cosmetic materials include cream, pasta,
Suitable examples include packs, emulsions, foundations, etc., but solids such as creams and packs and pastes are more suitable because of the large amount of zinc oxide compounded. These are commonly used components such as liquid paraffin as oil, ceresin, wax, lanolin, petrolatum, cetanol, squalene, jojoba oil, stearic acid, palmitic acid, lauryl alcohol, stearyl alcohol, cetyl alcohol, beeswax, methyl polysiloxane, Dimethylcyclopolysiloxane etc. are used, and moisturizing propanol, glycol, propylene glycol, hyaluronic acid, collagen, polyethylene glycol, cholesteryl hydroxystearate, glycerin, sorbitol and other various surfactants, emulsifiers, powdering agents, pH adjustment Agents, antioxidants, dyes, fragrances, ultraviolet absorbers and the like may be appropriately mixed.

【0013】[0013]

【発明の効果】以上のことから、本発明により、薬用化
粧品の有効成分として酸化亜鉛を適用することによっ
て、これまでの外用薬とは異なり、日常的に化粧品とし
て適用し、慢性の皮膚トラブルに長年悩み、あきらめさ
えしていた女性あるいは男性の肌を救う意義のある薬用
化粧品を提供することができた。
From the above, according to the present invention, by applying zinc oxide as an active ingredient of a cosmeceutical product, unlike conventional topical medicines, it is routinely applied as a cosmetic product to prevent chronic skin troubles. We have been able to provide a cosmeceutical product that has the meaning to save the skin of women or men who have long been worried and even gave up.

【0014】[0014]

【実施例】次に、本発明の実施例及びその試験結果をあ
げて説明する。対照として18才〜47才までの女性3
0例につき、本発明を提供した試験例を下記に示す。3
0例の内、ざそう20例、湿疹・皮膚炎群10例であっ
た。
EXAMPLES Next, examples of the present invention and test results thereof will be described. Females aged 18 to 47 as a reference 3
The test examples that provided the present invention per 0 examples are shown below. Three
Among 0 cases, 20 cases of acne and 10 cases of eczema / dermatitis group were included.

【0015】(症例の主な既往症状) (1)ざそう群20例について 皮膚病変の月経前増悪の有無:20例中20例にみ
られた。うち1例は、左卵巣嚢腫にて卵巣摘出術の手術
をうけていた。ホルモンバランスの乱れによる皮疹の増
悪は全例に認められた。 胃腸障害:20例中15例にみられた。便秘、下
痢、胃痛が主な症状で、ざそう治療により抗生剤等の薬
を内服すると、顕著に胃腸症状が出現するものは、10
例と半数にみられた。
(Major past symptoms of cases) (1) About 20 cases of acne group Presence or absence of premenstrual deterioration of skin lesions: It was observed in 20 cases out of 20 cases. One of them had undergone oophorectomy for left ovarian cyst. Exacerbation of the skin eruption due to disturbance of hormone balance was observed in all cases. Gastrointestinal disorders: found in 15 of 20 cases. Constipation, diarrhea, and stomach pain are the main symptoms, and when taking oral medicine such as antibiotics for acne treatment, notable gastrointestinal symptoms appear in 10 cases.
It was found in half of the cases.

【0016】(2) 湿疹・皮膚炎群10例について ホルモン剤による治療敬虔のあるもの10例中8例であ
った。化粧品かぶれの既往があるもの10例中7例であ
った。
(2) Ten cases of eczema / dermatitis group 8 cases out of 10 cases with pious treatment with hormones. There was a history of cosmetic rash in 7 of the 10 cases.

【0017】(30症例の罹病期間) 3カ月〜10年以上 この間、専門医を受診し治療を受けるも、再燃と寛解を
繰り返していたものは、30例中15例であった。
(Disease Duration of 30 Cases) 3 months to 10 years or more During this period, 15 out of 30 patients had repeated relapse and remission even though they visited a specialist and received treatment.

【0018】(化粧品の製法) 化粧品(a) クリーム 成 分 プラスチベース 50 % モノステアリン酸グリセリド 2.5% ポリオキシエチレンソルビタン− モノステアリン酸・エステル 1.5% 1.3−ブチレングリコール 5 % 香料 少々 酸化亜鉛 40 % 水 残量(Cosmetic manufacturing method) Cosmetic (a) Cream component Plastibase 50% Monostearic acid glyceride 2.5% Polyoxyethylene sorbitan-monostearic acid ester 1.5% 1.3-Butylene glycol 5% Perfume slightly zinc oxide 40% water remaining

【0019】製 法 プラスチベースを80℃に加温溶解し、これに乳化剤、
グリコール、香料、水の混合液を加えて予備乳化し、酸
化亜鉛を加えてホモミキサーで均一に懸濁化した後、3
0℃に冷却してクリームを得る。
Production method Plastibase is dissolved by heating at 80 ° C., and an emulsifier,
Add a mixture of glycol, fragrance and water to pre-emulsify, add zinc oxide and homogenize with a homomixer, then 3
Cool to 0 ° C. to obtain a cream.

【0020】化粧品(b) パック 成 分 ポリビニルアルコール 15% カルボキシメチルセルロース 5% プロピレングリコール 3% エタノール 2% 香料 少々 酸化亜鉛 40% 水 残量Cosmetics (b) Pack composition Polyvinyl alcohol 15% Carboxymethylcellulose 5% Propylene glycol 3% Ethanol 2% Perfume A little zinc oxide 40% Water remaining amount

【0021】製 法 酸化亜鉛以外の各成分を混合し、70℃に加温し強く攪
拌でに酸化亜鉛を加えて均一化し冷却して製品を得る。
Manufacturing Method Mixing each component other than zinc oxide, heating to 70 ° C. and adding zinc oxide by vigorous stirring to homogenize and cool to obtain a product.

【0022】(使用方法) 化粧品(a) の酸化亜鉛含有クリームを朝、夕、
1日2回化粧水の後に外用塗布する。1回の使用量は、
米粒大とした。 月経前増悪時など、皮疹の悪化をみたときは、化粧
品(b)のパックを用いてた。1カ月平均9回使用し
た。 * このクリーム以外の基礎化粧品は、従来使用してい
たものを引きつづき使用してもらい、従来の化粧品(市
販品名 花王ソフィーナ、クリニーク、アザレ、資生
堂、マックスファクター、鐘紡の各製品)を使用してい
た時の症状と比較検討した。尚、内服治療を先行してお
こなった重症例で、罹病期間が5年〜10年のものに対
しては、内服中止後より効果を判定した。
(How to use) The zinc oxide-containing cream of cosmetics (a) was used in the morning, evening,
Apply externally after lotion twice a day. The amount used once is
The size of rice grain was made. When the exacerbation of the rash was observed, such as during premenstrual exacerbation, the pack of cosmetics (b) was used. It was used 9 times a month on average. * For basic cosmetics other than this cream, we asked them to continue using the conventional cosmetics, and used conventional cosmetics (commercially available products Kao Sofina, Clinique, Azare, Shiseido, Max Factor, Kanebo). We compared it with the symptoms when it was struck. In addition, the effect was judged after the discontinuation of the oral administration in the severe cases in which the oral treatment was preceded and the disease duration was 5 to 10 years.

【0023】(使用期間) 3カ月以上(Period of use) 3 months or more

【0024】(試験結果) (1)ざそう群 全例に使用後1カ月以内で、月経前増悪時の個々の皮疹
の大きさが半分位におさえられ、使用以前のように強い
炎症をきたさず増大も認められなかった。その後、平均
3カ月以内に、それに加え、新生皮疹の劇的な減少認め
た。以後、何等かの因子により皮疹が一時的に再燃する
ことがあっても、従来のような悪化はみられなくなっ
た。一方、従来の化粧品使用例では、これまでと変わら
ず、ざそうの月経前憎悪の症状が認められた。
(Test Results) (1) Within one month after use, the size of each eruption during pre-menstrual exacerbation was reduced to about half in all cases of the acne group, resulting in strong inflammation as before use. No increase was observed. Thereafter, within an average of 3 months, in addition, a dramatic reduction in new skin rash was observed. After that, even if the skin rash temporarily recurred due to some factor, the conventional deterioration was no longer observed. On the other hand, in the case of using conventional cosmetics, the symptoms of premenstrual exacerbation of pimples were observed as usual.

【0025】(2)湿疹・皮膚炎群 使用1週間〜1カ月以内で、全例に皮疹の紅斑およびか
ゆみの軽減をみとめた。季節性、体調(睡眠、食事な
ど)如何にかかわらず、従来ほど皮疹の再燃は認められ
ず、かゆみ、紅斑等の出現頻度が減少した。
(2) Eczema / dermatitis group Within 1 week to 1 month of use, all the cases were found to reduce erythema and itchiness of the skin rash. Regardless of seasonality and physical condition (sleep, diet, etc.), the recurrence of the rash was not observed as much as before, and the frequency of itching, erythema, etc. decreased.

【0026】(外用剤の刺激およびアレルギー反応の検
討) 24時間closed patch test(コ
ントロールには白色ワセリンを用いた) 30例全例陰性であった。 使用テスト中の刺激反応及びアレルギー反応は、全
く認められなかった。
(Study of irritation of external preparation and allergic reaction) 24-hour closed patch test (white petrolatum was used as a control). All 30 cases were negative. No irritation or allergic reaction was observed during the use test.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 A61K 9/107 S 7329−4C 33/30 ADA 8314−4C ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Internal reference number FI Technical display location A61K 9/107 S 7329-4C 33/30 ADA 8314-4C

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 クリーム、パック、乳液、ファンデーシ
ョンなどの化粧品材料に酸化亜鉛が30〜60%(重
量)配合された薬用化粧品。
1. A cosmeceutical product containing 30 to 60% (by weight) of zinc oxide in a cosmetic material such as a cream, a pack, an emulsion or a foundation.
【請求項2】 ざそう、湿疹、皮膚炎の再燃予防用とし
て用いられる請求項1記載の薬用化粧品。
2. The cosmeceutical product according to claim 1, which is used for preventing relapse of acne, eczema and dermatitis.
【請求項3】 ざそう、湿疹、皮膚炎のでき易い肌質を
有する人、もしくはざそう、湿疹、皮膚炎の重症例患者
であって専門的治療により症例が軽快した人、に対する
再燃予防用に基礎化粧品材料として用いられる請求項2
記載の薬用化粧品。
3. For preventing flare-up, for a person who has a skin quality that is prone to acne, eczema, dermatitis, or a patient with severe cases of acne, eczema, and dermatitis whose case has been relieved by professional treatment. Used as a basic cosmetic material in
The cosmeceutical product described.
JP4169807A 1992-06-29 1992-06-29 Cosmetics Expired - Lifetime JP2697999B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4169807A JP2697999B2 (en) 1992-06-29 1992-06-29 Cosmetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4169807A JP2697999B2 (en) 1992-06-29 1992-06-29 Cosmetics

Publications (2)

Publication Number Publication Date
JPH069363A true JPH069363A (en) 1994-01-18
JP2697999B2 JP2697999B2 (en) 1998-01-19

Family

ID=15893265

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4169807A Expired - Lifetime JP2697999B2 (en) 1992-06-29 1992-06-29 Cosmetics

Country Status (1)

Country Link
JP (1) JP2697999B2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10324615A (en) * 1997-05-21 1998-12-08 Pola Chem Ind Inc Discrimination of cosmetic for pollinosis
JP2001240548A (en) * 1999-12-24 2001-09-04 Shiseido Co Ltd Inhibitor of plasminogen activator and combination skin external preparations
US6649179B2 (en) * 1999-12-24 2003-11-18 Shiseido Co., Ltd. Method for improving morbid dermatitis by inhibiting activity of a plasminogen activator in the skin
US6821523B2 (en) 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
US6943197B2 (en) 2002-06-21 2005-09-13 Howard I. Maibach Topical administration of pharmacologically active bases in the treatment of inflammatory dermatoses
JP2008545758A (en) * 2005-06-03 2008-12-18 プレザーコール, インコーポレイテッド Compositions containing elemental metals and uses thereof
JP2011032287A (en) * 2002-03-12 2011-02-17 Galderma Research & Development Pharmaceutical composition comprising adapalene for treatment of dermatological disorder
US10905894B2 (en) 2013-03-15 2021-02-02 Prezacor, Inc. Therapeutic bioelectromagnetic fields, pain relief devices, and related methods

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4975738A (en) * 1972-11-25 1974-07-22
DE3049038A1 (en) * 1980-12-24 1982-07-15 Marie 8000 München Hauck AGENTS FOR CONTROLLING SKIN DISEASES
JPS59134726A (en) * 1982-10-15 1984-08-02 ザ,プロクタ−,エンド,ギヤンブル,カンパニ− Storage stable local drug composition containing low dielectric solvent
JPS60161921A (en) * 1984-01-18 1985-08-23 ジヨンソン・アンド・ジヨンソン・ベイビー・プロダクツ・カンパニー Skin care composition
JPS6137711A (en) * 1984-07-31 1986-02-22 Shiseido Co Ltd Cosmetic
JPS61210018A (en) * 1985-03-15 1986-09-18 Shiseido Co Ltd Makeup cosmetic
JPS61236708A (en) * 1985-04-12 1986-10-22 Shiseido Co Ltd Cosmetic
JPS6256415A (en) * 1985-09-04 1987-03-12 Shiseido Co Ltd Cosmetic
JPH02289506A (en) * 1989-02-08 1990-11-29 Sakai Chem Ind Co Ltd Zinc oxide for cosmetic

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4975738A (en) * 1972-11-25 1974-07-22
DE3049038A1 (en) * 1980-12-24 1982-07-15 Marie 8000 München Hauck AGENTS FOR CONTROLLING SKIN DISEASES
JPS59134726A (en) * 1982-10-15 1984-08-02 ザ,プロクタ−,エンド,ギヤンブル,カンパニ− Storage stable local drug composition containing low dielectric solvent
JPS60161921A (en) * 1984-01-18 1985-08-23 ジヨンソン・アンド・ジヨンソン・ベイビー・プロダクツ・カンパニー Skin care composition
JPS6137711A (en) * 1984-07-31 1986-02-22 Shiseido Co Ltd Cosmetic
JPS61210018A (en) * 1985-03-15 1986-09-18 Shiseido Co Ltd Makeup cosmetic
JPS61236708A (en) * 1985-04-12 1986-10-22 Shiseido Co Ltd Cosmetic
JPS6256415A (en) * 1985-09-04 1987-03-12 Shiseido Co Ltd Cosmetic
JPH02289506A (en) * 1989-02-08 1990-11-29 Sakai Chem Ind Co Ltd Zinc oxide for cosmetic

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10324615A (en) * 1997-05-21 1998-12-08 Pola Chem Ind Inc Discrimination of cosmetic for pollinosis
JP2001240548A (en) * 1999-12-24 2001-09-04 Shiseido Co Ltd Inhibitor of plasminogen activator and combination skin external preparations
US6649179B2 (en) * 1999-12-24 2003-11-18 Shiseido Co., Ltd. Method for improving morbid dermatitis by inhibiting activity of a plasminogen activator in the skin
JP2011032287A (en) * 2002-03-12 2011-02-17 Galderma Research & Development Pharmaceutical composition comprising adapalene for treatment of dermatological disorder
US6821523B2 (en) 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
US6943197B2 (en) 2002-06-21 2005-09-13 Howard I. Maibach Topical administration of pharmacologically active bases in the treatment of inflammatory dermatoses
JP2008545758A (en) * 2005-06-03 2008-12-18 プレザーコール, インコーポレイテッド Compositions containing elemental metals and uses thereof
JP2013006872A (en) * 2005-06-03 2013-01-10 Prezacor Inc Composition containing elemental metal, and use of the same
US9173900B2 (en) 2005-06-03 2015-11-03 Prezacor, Inc. Compositions comprising elemental metals
US10195148B2 (en) 2005-06-03 2019-02-05 Prezacor, Inc. Pain relieving compositions comprising elemental metals
US10905894B2 (en) 2013-03-15 2021-02-02 Prezacor, Inc. Therapeutic bioelectromagnetic fields, pain relief devices, and related methods
US12102837B2 (en) 2013-03-15 2024-10-01 Gary A. Karpf Therapeutic bioelectromagnetic fields, pain relief devices, and related methods

Also Published As

Publication number Publication date
JP2697999B2 (en) 1998-01-19

Similar Documents

Publication Publication Date Title
US6667045B2 (en) Topical applications for skin treatment
EP0189738B1 (en) Topical compositions for preventing or treating dry skin
JP3513873B2 (en) External preparation for skin
US8512718B2 (en) Pharmaceutical composition for topical application
US6911211B2 (en) Pharmaceutical and cosmetic carrier or composition for topical application
JPH08505630A (en) Pharmaceutical and skin cosmetic compositions containing equine colostrum
JPH11501941A (en) Topical composition containing capsazepine
EP0687467A2 (en) Cosmetic and dermatological combinations containing glycerylalkylethers as active ingredients
JPH04124122A (en) Blackening agent of preventing gray hair
US6589540B1 (en) Cosmetic composition for skin care containing retinol and epidermal growth factor
DE10033717A1 (en) Cosmetic and dermatological preparation for removing sebum
JPH069363A (en) Medicinal cosmetic
JP2006321758A (en) Cosmetic
JP2676049B2 (en) Skin cosmetics
JP2720246B2 (en) External preparation for skin
JPH08104635A (en) External pharmaceutical preparation containing zinc phytate as active ingredient
JPH082772B2 (en) Sebum secretagogue
JPH11255661A (en) Preparation for external use for atopic dermatitis
JPS6011884B2 (en) Cosmetics for hair and skin care
KR101661694B1 (en) Low irritating composition for skin whitening comprising hydroquinone
JPH08268866A (en) Dermal preparation for external use
JP3193028B2 (en) External preparation for treating atopic dermatitis containing nitroimidazole compound
JP3193617B2 (en) Refreshing agent and composition for human body
RU2426540C1 (en) Anti-inflammatory and anti-allergic medication and based on it pharmaceutical composition
JP2002121108A (en) Skin care preparation for ameliorating chapped skin

Legal Events

Date Code Title Description
S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090919

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120919

Year of fee payment: 15

EXPY Cancellation because of completion of term